Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Glioblastoma mutliforme

- PMLiVE

NICE turns down first-line Keytruda for lung cancer

High cost of drug puts it above cost-effectiveness threshold

BMS appoints three independent directors

Robert Bertolini, Matthew Emmens and Theodore Samuels join the board

Deal Watch January 2017

Actelion, Johnson & Johnson, Sanofi, Takeda and more feature in this month's pharma deals round-up

- PMLiVE

Keytruda filed for first- and second-line bladder cancer

Merck & Co hopes to gain advantage over Opdivo and Tecentriq with first-line setting

- PMLiVE

Opdivo gets FDA green light to treat bladder cancer

BMS adds new US indication to its checkpoint inhibitor

Bristol-Myers Squibb (BMS) building

Opdivo drives growth at BMS, but US sales slow down

Sales beginning to lose momentum despite new indications bringing in $1.3bn for Q4

- PMLiVE

Merck settles PD-1 patent lawsuit with BMS and Ono

Agrees to pay $625m settlement plus royalties on sales of Keytruda until 2026

Bristol-Myers Squibb (BMS) building

BMS won’t seek quick okay for Opdivo combo in lung cancer

No longer intends to file for accelerated approval, pushing predicted approval date back to late 2018

Deal Watch December 2016

Allergan, AZ, BMS, Pfizer, Roche and more feature in this month's pharma deals round-up

AstraZeneca AZ

AZ tweaks immuno-oncology trials as it chases lung cancer leaders

Toughens targets for durvalumab in NSCLC monotherapy and combination study

- PMLiVE

Merck & Co’s Keytruda muscles further ahead of rivals in lung cancer

Granted accelerated review by FDA for use in combination with chemotherapy

- PMLiVE

BMS names chairman of the board

Giovanni Caforio to succeed Lamberto Andreotti on 2 May

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links